摘要 |
Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound of Formula (I): wherein X is C-R', C-OR', C-CH2-OR' wherein R' is selected from the group consisting of H, C1-C5 alkyl, an aromatic group containing species and alkyl-, halo-, or amino-substituted aromatic group containing species; E' is hydrogen or C1-C5 alkyl or halo substituted C1-C5 alkyl; E'' is C1-C5 alkyl or halo substituted C1-C5 alkyl; Z' and Z'' are each individually selected from the group consisting of hydrogen, C1-C5 alkyl, aryl rings, and can form a ring structure (a), A, A' and A'' are each individually selected from the group consisting of hydrogen, C1-C7 alkyl, and halo; m is 0 or 1; p is 0 or 1 with the proviso that when m or p is 0 then that E'' is hydrogen; and the wavy line in the structure represents a cis (Z) or trans (E) form of the compound. Exemplary compounds include (E)-N-methyl-4-¢3-(benzyloxypyridin)yl!-3-buten-1-amine, (E)-N-methyl-4-¢3-(5-phenoxypyridin)yl!-3-buten-1-amine, (E)-N-methyl-4-¢3-(5-isopropoxypyridin)yl!-3-buten-1-amine, (E)-N-methyl-4-¢3-(5-methoxymethylpyridin)yl!-3-buten-1-amine, and (E)-N-methyl-4-¢3-(5-phenylpyridin)yl!-3-buten-1-amine. |
申请人 |
R.J. REYNOLDS TOBACCO COMPANY |
发明人 |
LIPPIELLO, PATRICK MICHAEL;CALDWELL, WILLIAM SCOTT;DULL, GARY MAURICE;BENCHERIF, MEROUANE;DOBSON, GRAYLAND PAGE;MILLER, CRAIG HARRISON |